{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:01:15Z","timestamp":1793944875035,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["20-315-90041"],"award-info":[{"award-number":["20-315-90041"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["19-29-04113-mk"],"award-info":[{"award-number":["19-29-04113-mk"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"crossref","award":["075-15-2019-1669"],"award-info":[{"award-number":["075-15-2019-1669"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dozens of transplants generated from pluripotent stem cells are currently in clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible due to their main advantage of immunotolerance. However, some reports have claimed recently that aberrant gene expression followed by proteome alterations and neoantigen formation can result in iPSCs recognition by autologous T-cells. Meanwhile, the possibility of NK-cell activation has not been previously considered. This study focused on the comparison of autologous and allogeneic immune response to iPSC-derived cells and isogeneic parental somatic cells used for reprogramming.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established an isogeneic cell model consisting of parental dermal fibroblasts, fibroblast-like iPSC-derivatives (iPS-fibro) and iPS-fibro lacking beta-2-microglobulin (B2M). Using the cells obtained from two patients, we analyzed the activation of autologous and allogeneic T-lymphocytes and NK-cells co-cultured with target cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here we report that cells differentiated from iPSCs can be recognized by NK-cells rather than by autologous T-cells. We observed that iPS-fibro elicited a high level of NK-cell degranulation and cytotoxicity, while isogeneic parental skin fibroblasts used to obtain iPSCs barely triggered an NK-cell response. iPSC-derivatives with\n                      <jats:italic>B2M<\/jats:italic>\n                      knockout did not cause an additional increase in NK-cell activation, although they were devoid of HLA-I, the major inhibitory molecules for NK-cells. Transcriptome analysis revealed a significant imbalance of ligands for activating and inhibitory NK-cell receptors in iPS-fibro. Compared to parental fibroblasts, iPSC-derivatives had a reduced expression of HLA-I simultaneously with an increased gene expression of major activating ligands, such as\n                      <jats:italic>MICA<\/jats:italic>\n                      ,\n                      <jats:italic>NECTIN2<\/jats:italic>\n                      , and\n                      <jats:italic>PVR<\/jats:italic>\n                      . The lack of inhibitory signals might be due to insufficient maturity of cells differentiated from iPSCs. In addition, we showed that pretreatment of iPS-fibro with proinflammatory cytokine IFN\u03b3 restored the ligand imbalance, thereby reducing the degranulation and cytotoxicity of NK-cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, we showed that iPSC-derived cells can be sensitive to the cytotoxic potential of autologous NK-cells regardless of HLA-I status. Thus, the balance of ligands for NK-cell receptors should be considered prior to iPSC-based cell therapies.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      Not applicable.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-023-03308-5","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T20:02:31Z","timestamp":1681156951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-6891","authenticated-orcid":false,"given":"Margarita E.","family":"Bogomiakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta K.","family":"Sekretova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia S.","family":"Anufrieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina O.","family":"Khabarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia N.","family":"Kazakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel A.","family":"Bobrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Grigoryeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem V.","family":"Eremeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga S.","family":"Lebedeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N.","family":"Bogomazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lagarkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"issue":"5391","key":"3308_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","volume":"282","author":"JA Thomson","year":"1998","unstructured":"Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145\u20137.","journal-title":"Science"},{"issue":"5","key":"3308_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372.","journal-title":"Cell"},{"issue":"1","key":"3308_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.stem.2017.12.003","volume":"22","author":"F Suchy","year":"2018","unstructured":"Suchy F, Yamaguchi T, Nakauchi H. iPSC-Derived organs in vivo: challenges and promise. Cell Stem Cell. 2018;22(1):21\u20134.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3308_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13287-015-0089-y","volume":"6","author":"A Peloso","year":"2015","unstructured":"Peloso A, Dhal A, Zambon JP, et al. Current achievements and future perspectives in whole-organ bioengineering. Stem Cell Res Ther. 2015;6(1):107.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"3308_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","volume":"16","author":"G Liu","year":"2020","unstructured":"Liu G, David BT, Trawczynski M, Fessler RG. Advances in pluripotent stem cells: history, mechanisms, technologies, and applications. Stem Cell Rev Rep. 2020;16(1):3\u201332.","journal-title":"Stem Cell Rev Rep"},{"issue":"2","key":"3308_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.stemcr.2020.06.014","volume":"15","author":"S Kobold","year":"2020","unstructured":"Kobold S, Guhr A, Mah N, et al. A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells. Stem Cell Reports. 2020;15(2):546\u201355.","journal-title":"Stem Cell Reports"},{"issue":"5","key":"3308_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/cells8050403","volume":"8","author":"MX Doss","year":"2019","unstructured":"Doss MX, Sachinidis A. Current challenges of IPSC-based disease modeling and therapeutic implications. Cells. 2019;8(5):403.","journal-title":"Cells"},{"issue":"1","key":"3308_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-019-0578-x","volume":"26","author":"CY Huang","year":"2019","unstructured":"Huang CY, Liu CL, Ting CY, et al. Human iPSC banking: barriers and opportunities. J Biomed Sci. 2019;26(1):87.","journal-title":"J Biomed Sci"},{"issue":"7","key":"3308_CR9","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/ijms21072435","volume":"21","author":"D Rehakova","year":"2020","unstructured":"Rehakova D, Souralova T, Koutna I. Clinical-grade human pluripotent stem cells for cell therapy: characterization strategy. Int J Mol Sci. 2020;21(7):2435.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3308_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/rme-2018-0095","volume":"13","author":"S Sullivan","year":"2018","unstructured":"Sullivan S, Stacey GN, Akazawa C, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13(7):859\u201366.","journal-title":"Regen Med"},{"issue":"3","key":"3308_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/rme.15.11","volume":"10","author":"EM Bolton","year":"2015","unstructured":"Bolton EM, Bradley JA. Avoiding immunological rejection in regenerative medicine. Regen Med. 2015;10(3):287\u2013304.","journal-title":"Regen Med"},{"issue":"6","key":"3308_CR12","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.isci.2020.101162","volume":"23","author":"W Zhao","year":"2020","unstructured":"Zhao W, Lei A, Tian L, et al. Strategies for genetically engineering hypoimmunogenic universal pluripotent stem cells. iScience. 2020;23(6):101162.","journal-title":"iScience"},{"issue":"9","key":"3308_CR13","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/stem.2407","volume":"34","author":"D Zheng","year":"2016","unstructured":"Zheng D, Wang X, Xu RH. Concise review: one stone for multiple birds: generating universally compatible human embryonic stem cells. Stem Cells. 2016;34(9):2269\u201375.","journal-title":"Stem Cells"},{"issue":"5","key":"3308_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1134\/S0026893319050042","volume":"53","author":"ME Bogomiakova","year":"2019","unstructured":"Bogomiakova ME, Eremeev AV, Lagarkova MA. At home among strangers: is it possible to create hypoimmunogenic pluripotent stem cell lines? Mol Biol. 2019;53(5):725\u201340.","journal-title":"Mol Biol"},{"issue":"6","key":"3308_CR15","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/mt.2013.59","volume":"21","author":"L Riolobos","year":"2013","unstructured":"Riolobos L, Hirata RK, Turtle CJ, et al. HLA engineering of human pluripotent stem cells. Mol Ther. 2013;21(6):1232\u201341.","journal-title":"Mol Ther"},{"issue":"6","key":"3308_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12015-013-9457-0","volume":"9","author":"P Lu","year":"2013","unstructured":"Lu P, Chen J, He L, et al. Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin. Stem Cell Rev Rep. 2013;9(6):806\u201313.","journal-title":"Stem Cell Rev Rep"},{"issue":"10","key":"3308_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","volume":"4","author":"D Wang","year":"2015","unstructured":"Wang D, Quan Y, Yan Q, Morales JE, Wetsel RA. Targeted disruption of the \u03b22-microglobulin gene minimizes the immunogenicity of human embryonic stem cells. Stem Cells Transl Med. 2015;4(10):1234\u201345.","journal-title":"Stem Cells Transl Med"},{"issue":"11","key":"3308_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/stem.3269","volume":"38","author":"L Shi","year":"2020","unstructured":"Shi L, Li W, Liu Y, et al. Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted \u03b22m-HLA-G fusion proteins. Stem Cells. 2020;38(11):1423\u201337.","journal-title":"Stem Cells"},{"issue":"1","key":"3308_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.stemcr.2019.11.011","volume":"14","author":"D Suzuki","year":"2020","unstructured":"Suzuki D, Flahou C, Yoshikawa N, et al. iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity. Stem Cell Rep. 2020;14(1):49\u201359.","journal-title":"Stem Cell Rep"},{"key":"3308_CR20","doi-asserted-by":"publisher","first-page":"102451","DOI":"10.1016\/j.scr.2021.102451","volume":"55","author":"ME Bogomiakova","year":"2021","unstructured":"Bogomiakova ME, Sekretova EK, Eremeev AV, et al. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR\/Cas9 genome editing. Stem Cell Res. 2021;55:102451.","journal-title":"Stem Cell Res"},{"issue":"1","key":"3308_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13287-022-02720-7","volume":"13","author":"C Song","year":"2022","unstructured":"Song C, Wang L, Li Q, et al. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells. Stem Cell Res Ther. 2022;13(1):48.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"3308_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai H, Reik A, Soldner F, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013;122(8):1341\u20139.","journal-title":"Blood"},{"issue":"21","key":"3308_CR23","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","volume":"116","author":"X Han","year":"2019","unstructured":"Han X, Wang M, Duan S, et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc Natl Acad Sci U S A. 2019;116(21):10441\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3308_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu H, Wang B, Ono M, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell. 2019;24(4):566-578.e7.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"3308_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s12015-020-10113-7","volume":"17","author":"A Kim","year":"2021","unstructured":"Kim A, Lee KG, Kwon Y, et al. Off-the-shelf, immune-compatible human embryonic stem cells generated via CRISPR-mediated genome editing. Stem Cell Rev Rep. 2021;17(3):1053\u201367.","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"3308_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","volume":"19","author":"R Lanza","year":"2019","unstructured":"Lanza R, Russell DW, Nagy A. Engineering universal cells that evade immune detection. Nat Rev Immunol. 2019;19(12):723\u201333.","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"3308_CR27","doi-asserted-by":"publisher","first-page":"e010239","DOI":"10.1161\/JAHA.118.010239","volume":"7","author":"S Mattapally","year":"2018","unstructured":"Mattapally S, Pawlik KM, Fast VG, et al. Human leukocyte antigen class i and ii knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy. J Am Heart Assoc. 2018;7(23):e010239.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"3308_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37(3):252\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3308_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s13287-020-01847-9","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Lu M, Tian X, et al. Diminished expression of major histocompatibility complex facilitates the use of human induced pluripotent stem cells in monkey. Stem Cell Res Ther. 2020;11(1):334.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"3308_CR30","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.stemcr.2020.02.006","volume":"14","author":"S Petrus-Reurer","year":"2020","unstructured":"Petrus-Reurer S, Winblad N, Kumar P, et al. Generation of retinal pigment epithelial cells derived from human embryonic stem cells lacking human leukocyte antigen class I and II. Stem Cell Rep. 2020;14(4):648\u201362.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"3308_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang B, Iriguchi S, Waseda M, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021;5(5):429\u201340.","journal-title":"Nat Biomed Eng"},{"key":"3308_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41232-020-00132-9","volume":"40","author":"K Koga","year":"2020","unstructured":"Koga K, Wang B, Kaneko S. Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflamm Regen. 2020;40:23.","journal-title":"Inflamm Regen"},{"issue":"7","key":"3308_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","volume":"11","author":"HG Ljunggren","year":"1990","unstructured":"Ljunggren HG, K\u00e4rre K. In search of the \u201cmissing self\u201d: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237\u201344.","journal-title":"Immunol Today"},{"key":"3308_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"3308_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse GG, Hirata RK, Funk SE, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765\u201372.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3308_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.stem.2020.02.006","volume":"26","author":"BJ Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez BJ, Creusot RJ, Sykes M, Egli D. How safe are universal pluripotent stem cells? Cell Stem Cell. 2020;26(3):307\u20138.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"3308_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.stemcr.2022.02.014","volume":"17","author":"F Matheus","year":"2022","unstructured":"Matheus F, Raveh T, Oro AE, Wernig M, Drukker M. Is hypoimmunogenic stem cell therapy safe in times of pandemics? Stem Cell Rep. 2022;17(4):711\u20134.","journal-title":"Stem Cell Rep"},{"issue":"164","key":"3308_CR38","doi-asserted-by":"publisher","first-page":"164ps25","DOI":"10.1126\/scitranslmed.3005090","volume":"4","author":"JI Pearl","year":"2012","unstructured":"Pearl JI, Kean LS, Davis MM, Wu JC. Pluripotent stem cells: immune to the immune system? Sci Transl Med. 2012;4(164):164ps25.","journal-title":"Sci Transl Med"},{"issue":"7350","key":"3308_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature10135","volume":"474","author":"T Zhao","year":"2011","unstructured":"Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212\u20135.","journal-title":"Nature"},{"issue":"3","key":"3308_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.stem.2015.07.021","volume":"17","author":"T Zhao","year":"2015","unstructured":"Zhao T, Zhang ZN, Westenskow PD, et al. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell. 2015;17(3):353\u20139.","journal-title":"Cell Stem Cell"},{"key":"3308_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fimmu.2017.00645","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Li W, Fu X, Xu Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front Immunol. 2017;8:645.","journal-title":"Front Immunol"},{"issue":"10","key":"3308_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41587-019-0227-7","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Agbor-Enoh S, et al. De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. Nat Biotechnol. 2019;37(10):1137\u201344.","journal-title":"Nat Biotechnol"},{"issue":"W1","key":"3308_CR43","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46(W1):W242\u20135.","journal-title":"Nucleic Acids Res"},{"key":"3308_CR44","doi-asserted-by":"publisher","first-page":"102431","DOI":"10.1016\/j.scr.2021.102431","volume":"54","author":"LD Shuvalova","year":"2021","unstructured":"Shuvalova LD, Davidenko AV, Eremeev AV, et al. Generation of induced pluripotent stem cell line RCPCMi008-A derived from patient with spinocerebellar ataxia 17. Stem Cell Res. 2021;54:102431.","journal-title":"Stem Cell Res"},{"issue":"2","key":"3308_CR45","doi-asserted-by":"publisher","first-page":"e17128","DOI":"10.1371\/journal.pone.0017128","volume":"6","author":"KJ Hewitt","year":"2011","unstructured":"Hewitt KJ, Shamis Y, Hayman RB, et al. Epigenetic and phenotypic profile of fibroblasts derived from induced pluripotent stem cells. PLoS ONE. 2011;6(2):e17128.","journal-title":"PLoS ONE"},{"issue":"3","key":"3308_CR46","first-page":"321","volume":"84","author":"AV Eremeev","year":"2019","unstructured":"Eremeev AV, Volovikov EA, Shuvalova LD, et al. \u201cNecessity is the mother of invention\u201d or inexpensive, reliable, and reproducible protocol for generating organoids. Biochemistry. 2019;84(3):321\u20138.","journal-title":"Biochemistry"},{"key":"3308_CR47","doi-asserted-by":"publisher","first-page":"625231","DOI":"10.3389\/fcell.2021.625231","volume":"9","author":"VA Vigont","year":"2021","unstructured":"Vigont VA, Grekhnev DA, Lebedeva OS, et al. STIM2 mediates excessive store-operated calcium entry in patient-specific iPSC-derived neurons modeling a juvenile form of huntington\u2019s disease. Front Cell Dev Biol. 2021;9:625231.","journal-title":"Front Cell Dev Biol"},{"key":"3308_CR48","unstructured":"Human Pluripotent Stem Cell Registry. https:\/\/hpscreg.eu\/cell-line\/RCPCMi007-A"},{"issue":"11","key":"3308_CR49","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"issue":"1","key":"3308_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13059-021-02293-3","volume":"22","author":"D Neavin","year":"2021","unstructured":"Neavin D, Nguyen Q, Daniszewski MS, et al. Single cell eQTL analysis identifies cell type-specific genetic control of gene expression in fibroblasts and reprogrammed induced pluripotent stem cells. Genome Biol. 2021;22(1):76.","journal-title":"Genome Biol"},{"issue":"7564","key":"3308_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature14546","volume":"524","author":"H Ma","year":"2015","unstructured":"Ma H, Folmes CD, Wu J, et al. Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature. 2015;524(7564):234\u20138.","journal-title":"Nature"},{"issue":"2","key":"3308_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cell.2015.06.016","volume":"162","author":"D Cacchiarelli","year":"2015","unstructured":"Cacchiarelli D, Trapnell C, Ziller MJ, et al. Integrative analyses of human reprogramming reveal dynamic nature of induced pluripotency. Cell. 2015;162(2):412\u201324.","journal-title":"Cell"},{"issue":"11","key":"3308_CR53","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nbt.3388","volume":"33","author":"J Choi","year":"2015","unstructured":"Choi J, Lee S, Mallard W, et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat Biotechnol. 2015;33(11):1173\u201381.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"3308_CR54","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.4049\/jimmunol.1700394","volume":"199","author":"P Netter","year":"2017","unstructured":"Netter P, Anft M, Watzl C. Termination of the activating NK cell immunological synapse is an active and regulated process. J Immunol. 2017;199(7):2528\u201335.","journal-title":"J Immunol"},{"issue":"15","key":"3308_CR55","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1073\/pnas.142298299","volume":"99","author":"M Drukker","year":"2002","unstructured":"Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A. 2002;99(15):9864\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3308_CR56","doi-asserted-by":"publisher","first-page":"e1509819","DOI":"10.1080\/2162402X.2018.1509819","volume":"7","author":"JL Oyer","year":"2018","unstructured":"Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology. 2018;7(11):e1509819.","journal-title":"Oncoimmunology"},{"issue":"6","key":"3308_CR57","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/jcm8060842","volume":"8","author":"A Park","year":"2019","unstructured":"Park A, Yang Y, Lee Y, et al. Indoleamine-2,3-dioxygenase in thyroid cancer cells suppresses natural killer cell function by inhibiting NKG2D and NKp46 expression via STAT signaling pathways. J Clin Med. 2019;8(6):842.","journal-title":"J Clin Med"},{"issue":"3","key":"3308_CR58","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1002\/cpz1.88","volume":"1","author":"M Madrid","year":"2021","unstructured":"Madrid M, Sumen C, Aivio S, Saklayen N. Autologous induced pluripotent stem cell-based cell therapies: promise, progress, and challenges. Curr Protoc. 2021;1(3):e88.","journal-title":"Curr Protoc"},{"issue":"11","key":"3308_CR59","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):1038\u201346.","journal-title":"N Engl J Med"},{"key":"3308_CR60","doi-asserted-by":"crossref","unstructured":"Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells [published correction appears in Cell Stem Cell. 2017 Jul 6;21(1):144\u2013148].\u00a0Cell Stem Cell. 2013;12(4):407\u2013412.","DOI":"10.1016\/j.stem.2013.01.006"},{"issue":"7435","key":"3308_CR61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature11807","volume":"494","author":"R Araki","year":"2013","unstructured":"Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013;494(7435):100\u20134.","journal-title":"Nature"},{"issue":"3","key":"3308_CR62","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/CIRCRESAHA.111.249243","volume":"112","author":"PE de Almeida","year":"2013","unstructured":"de Almeida PE, Ransohoff JD, Nahid A, Wu JC. Immunogenicity of pluripotent stem cells and their derivatives. Circ Res. 2013;112(3):549\u201361.","journal-title":"Circ Res"},{"issue":"7","key":"3308_CR63","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1096\/fj.09-134957","volume":"24","author":"R Dressel","year":"2010","unstructured":"Dressel R, Nolte J, Elsner L, et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J. 2010;24(7):2164\u201377.","journal-title":"FASEB J"},{"issue":"5","key":"3308_CR64","doi-asserted-by":"publisher","first-page":"e0125544","DOI":"10.1371\/journal.pone.0125544","volume":"10","author":"V Kruse","year":"2015","unstructured":"Kruse V, Hamann C, Monecke S, et al. Human induced pluripotent stem cells are targets for allogeneic and autologous natural killer (NK) cells and killing is partly mediated by the activating NK receptor DNAM-1. PLoS ONE. 2015;10(5):e0125544.","journal-title":"PLoS ONE"},{"key":"3308_CR65","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3389\/fimmu.2017.00870","volume":"8","author":"C Gr\u00f6schel","year":"2017","unstructured":"Gr\u00f6schel C, H\u00fcbscher D, Nolte J, et al. Efficient killing of murine pluripotent stem cells by natural killer (NK) cells requires activation by cytokines and partly depends on the activating NK receptor NKG2D. Front Immunol. 2017;8:870.","journal-title":"Front Immunol"},{"key":"3308_CR66","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3389\/fimmu.2019.02580","volume":"10","author":"B Benabdallah","year":"2019","unstructured":"Benabdallah B, D\u00e9saulniers-Langevin C, Colas C, et al. Natural killer cells prevent the formation of teratomas derived from human induced pluripotent stem cells. Front Immunol. 2019;10:2580.","journal-title":"Front Immunol"},{"issue":"6","key":"3308_CR67","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/ajt.15217","volume":"19","author":"T Cisneros","year":"2019","unstructured":"Cisneros T, Dillard DW, Qu X, et al. Differential role of natural killer group 2D in recognition and cytotoxicity of hepatocyte-like cells derived from embryonic stem cells and induced pluripotent stem cells. Am J Transplant. 2019;19(6):1652\u201362.","journal-title":"Am J Transplant"},{"issue":"1","key":"3308_CR68","doi-asserted-by":"publisher","first-page":"10840","DOI":"10.1038\/s41598-019-47134-3","volume":"9","author":"Y Nakamura","year":"2019","unstructured":"Nakamura Y, Miyagawa S, Yoshida S, et al. Natural killer cells impede the engraftment of cardiomyocytes derived from induced pluripotent stem cells in syngeneic mouse model. Sci Rep. 2019;9(1):10840.","journal-title":"Sci Rep"},{"issue":"2","key":"3308_CR69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/icb.2010.78","volume":"89","author":"HJ Pegram","year":"2011","unstructured":"Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216\u201324.","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"3308_CR70","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1615\/CritRevImmunol.v22.i4.50","volume":"22","author":"LG Hidalgo","year":"2002","unstructured":"Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol. 2002;22(4):317\u201349.","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"3308_CR71","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41598-020-79664-6","volume":"11","author":"R Kanai","year":"2021","unstructured":"Kanai R, Nakashima A, Doi S, et al. Interferon-\u03b3 enhances the therapeutic effect of mesenchymal stem cells on experimental renal fibrosis. Sci Rep. 2021;11(1):850.","journal-title":"Sci Rep"},{"issue":"4","key":"3308_CR72","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000324400","volume":"3","author":"J Villard","year":"2011","unstructured":"Villard J. The role of natural killer cells in human solid organ and tissue transplantation. J Innate Immun. 2011;3(4):395\u2013402.","journal-title":"J Innate Immun"},{"key":"3308_CR73","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3389\/fimmu.2020.01454","volume":"11","author":"P Pontrelli","year":"2020","unstructured":"Pontrelli P, Rascio F, Castellano G, Grandaliano G, Gesualdo L, Stallone G. The role of natural killer cells in the immune response in kidney transplantation. Front Immunol. 2020;11:1454.","journal-title":"Front Immunol"},{"issue":"10","key":"3308_CR74","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1097\/TP.0000000000001914","volume":"101","author":"A Adenugba","year":"2017","unstructured":"Adenugba A. NK cells in transplantation. Transplantation. 2017;101(10):2262\u20134.","journal-title":"Transplantation"},{"issue":"10","key":"3308_CR75","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.oret.2019.04.021","volume":"3","author":"S Takagi","year":"2019","unstructured":"Takagi S, Mandai M, Gocho K, et al. Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration. Ophthalmol Retina. 2019;3(10):850\u20139.","journal-title":"Ophthalmol Retina"},{"issue":"20","key":"3308_CR76","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for parkinson\u2019s disease. N Engl J Med. 2020;382(20):1926\u201332.","journal-title":"N Engl J Med"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-023-03308-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T07:47:43Z","timestamp":1702194463000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-023-03308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3308"],"URL":"https:\/\/doi.org\/10.1186\/s13287-023-03308-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2042042\/v1","asserted-by":"object"}]},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved on June 1, 2021 by the Ethics Committee of the Federal Research Clinical Center of Physical and Chemical Medicine (protocol number 2021\u201306-01\/1, project title \u201cImmunogenic properties of differentiated derivatives of human induced pluripotent stem cells\u201d). All donor samples were obtained in accordance with the Declaration of Helsinki principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}